{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:29:41Z","timestamp":1792150181403,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"SI2","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Duke Children\u2019s Office of Development"},{"DOI":"10.13039\/100018268","name":"Children\u2019s Miracle Network Hospitals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018208","name":"Cure JM Foundation","doi-asserted-by":"publisher","award":["63022"],"award-info":[{"award-number":["63022"]}],"id":[{"id":"10.13039\/100018208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UH3TR002142"],"award-info":[{"award-number":["UH3TR002142"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eunice Kennedy Shriver National Institute of Child Health & Development","award":["T32 [HD094671"],"award-info":[{"award-number":["T32 [HD094671"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To better understand the pathogenesis of juvenile dermatomyositis (JDM), we examined the effect of the cytokines type I interferons (IFN I) and JAK inhibitor drugs (JAKi) on gene expression in bioengineered pediatric skeletal muscle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Myoblasts from three healthy pediatric donors were used to create three-dimensional skeletal muscle units termed myobundles. Myobundles were treated with IFN I, either IFN\u03b1 or IFN\u03b2. A subset of IFN\u03b2-exposed myobundles was treated with JAKi tofacitinib or baricitinib. RNA sequencing analysis was performed on all myobundles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-six myobundles were analysed. Principal component analysis showed donor-specific clusters of gene expression across IFN\u03b1 and IFN\u03b2-exposed myobundles in a dose-dependent manner. Both cytokines upregulated interferon response and proinflammatory genes; however, IFN\u03b2 led to more significant upregulation. Key downregulated pathways involved oxidative phosphorylation, fatty acid metabolism and myogenesis genes. Addition of tofacitinib or baricitinib moderated the gene expression induced by IFN\u03b2, with partial reversal of upregulated inflammatory and downregulated myogenesis pathways. Baricitinib altered genetic profiles more than tofacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IFN\u03b2 leads to more pro-inflammatory gene upregulation than IFN\u03b1, correlating to greater decrease in contractile protein gene expression and reduced contractile force. JAK inhibitors, baricitinib more so than tofacitinib, partially reverse IFN I-induced genetic changes. Increased IFN I exposure in healthy bioengineered skeletal muscle leads to IFN-inducible gene expression, inflammatory pathway enrichment, and myogenesis gene downregulation, consistent with what is observed in JDM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae082","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T17:11:39Z","timestamp":1706807499000},"page":"SI240-SI248","source":"Crossref","is-referenced-by-count":12,"title":["Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-5635","authenticated-orcid":false,"given":"Lauren T","family":"Covert","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Duke University Health System , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Prinz","sequence":"additional","affiliation":[{"name":"Sequencing and Genomics Technologies Core Facility, School of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devjanee","family":"Swain-Lenz","sequence":"additional","affiliation":[{"name":"Sequencing and Genomics Technologies Core Facility, School of Medicine, Duke University , Durham, NC, USA"},{"name":"Department of Molecular Genetics and Microbiology, School of Medicine, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Dvergsten","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University Health System , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Truskey","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Duke University , Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"2024090907513572300_keae082-B1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.41615","article-title":"Comparison of lesional juvenile myositis and lupus skin reveals overlapping yet unique disease pathophysiology","volume":"73","author":"Turnier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024090907513572300_keae082-B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024090907513572300_keae082-B3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2024090907513572300_keae082-B4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024090907513572300_keae082-B5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024090907513572300_keae082-B6","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"2024090907513572300_keae082-B7","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"2024090907513572300_keae082-B8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","article-title":"Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis","volume":"63","author":"Covert","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024090907513572300_keae082-B9","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA10501+ children with untreated dermatomyositis: a novel model of pathogenesis","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"2024090907513572300_keae082-B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092786","article-title":"Expression of the OAS gene family is highly modulated in subjects affected by juvenile dermatomyositis, resembling an immune response to a dsRNA virus infection","volume":"19","author":"Musumeci","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2024090907513572300_keae082-B11","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s10439-019-02263-8","article-title":"Modeling the effect of TNF-alpha upon drug-induced toxicity in human, tissue-engineered myobundles","volume":"47","author":"Davis","year":"2019","journal-title":"Ann Biomed Eng"},{"key":"2024090907513572300_keae082-B12","doi-asserted-by":"crossref","first-page":"e04885","DOI":"10.7554\/eLife.04885","article-title":"Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs","volume":"4","author":"Madden","year":"2015","journal-title":"eLife"},{"key":"2024090907513572300_keae082-B13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis","volume":"12(Suppl 1)","author":"Greenberg","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024090907513572300_keae082-B14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.actbio.2021.03.007","article-title":"Loss of sarcomeric proteins via upregulation of JAK\/STAT signaling underlies interferon-\u03b3-induced contractile deficit in engineered human myocardium","volume":"126","author":"Zhan","year":"2021","journal-title":"Acta Biomater"},{"key":"2024090907513572300_keae082-B15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd9502","article-title":"Exercise mimetics and JAK inhibition attenuate IFN-\u03b3-induced wasting in engineered human skeletal muscle","volume":"7","author":"Chen","year":"2021","journal-title":"Sci Adv"},{"key":"2024090907513572300_keae082-B16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.113.209304","article-title":"Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis","volume":"348","author":"Dowty","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2024090907513572300_keae082-B17","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2024090907513572300_keae082-B18","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"2024090907513572300_keae082-B19","doi-asserted-by":"crossref","first-page":"D91","DOI":"10.1093\/nar\/gkr895","article-title":"Ensembl Genomes: an integrative resource for genome-scale data from non-vertebrate species","volume":"40","author":"Kersey","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2024090907513572300_keae082-B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2024090907513572300_keae082-B21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2024090907513572300_keae082-B22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nmeth.3252","article-title":"Orchestrating high-throughput genomic analysis with Bioconductor","volume":"12","author":"Huber","year":"2015","journal-title":"Nat Methods"},{"key":"2024090907513572300_keae082-B23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nmeth.3885","article-title":"Data-driven hypothesis weighting increases detection power in genome-scale multiple testing","volume":"13","author":"Ignatiadis","year":"2016","journal-title":"Nat Methods"},{"key":"2024090907513572300_keae082-B24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"2024090907513572300_keae082-B25","first-page":"275","article-title":"False discovery rates: a new deal","volume":"18","author":"Stephens","year":"2017","journal-title":"Biostatistics"},{"key":"2024090907513572300_keae082-B26","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024090907513572300_keae082-B27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2024090907513572300_keae082-B28","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2024090907513572300_keae082-B29","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050480","article-title":"Long noncoding RNA HCP5, a hybrid HLA class I endogenous retroviral gene: structure, expression, and disease associations","volume":"8","author":"Kulski","year":"2019","journal-title":"Cells"},{"key":"2024090907513572300_keae082-B30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024090907513572300_keae082-B31","doi-asserted-by":"crossref","first-page":"C381","DOI":"10.1152\/ajpcell.00317.2015","article-title":"Myosin content of individual human muscle fibers isolated by laser capture microdissection","volume":"310","author":"Stuart","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"2024090907513572300_keae082-B32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13395-015-0046-6","article-title":"Developmental myosins: expression patterns and functional significance","volume":"5","author":"Schiaffino","year":"2015","journal-title":"Skeletal Muscle"},{"key":"2024090907513572300_keae082-B33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.gene.2015.10.052","article-title":"TNNI1, TNNI2 and TNNI3: evolution, regulation, and protein structure-function relationships","volume":"576","author":"Sheng","year":"2016","journal-title":"Gene"},{"key":"2024090907513572300_keae082-B34","doi-asserted-by":"crossref","first-page":"32818","DOI":"10.1038\/srep32818","article-title":"Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"key":"2024090907513572300_keae082-B35","doi-asserted-by":"crossref","first-page":"e12841","DOI":"10.1111\/nan.12841","article-title":"Respiratory chain dysfunction in perifascicular muscle fibres in patients with dermatomyositis is associated with mitochondrial DNA depletion","volume":"48","author":"Hedberg-Oldfors","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2024090907513572300_keae082-B36","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/brain\/awf163","article-title":"Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study","volume":"125","author":"Cea","year":"2002","journal-title":"Brain"},{"key":"2024090907513572300_keae082-B37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"2024090907513572300_keae082-B38","doi-asserted-by":"crossref","first-page":"103061","DOI":"10.1016\/j.jaut.2023.103061","article-title":"Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis","volume":"138","author":"Duvvuri","year":"2023","journal-title":"J Autoimmun"},{"key":"2024090907513572300_keae082-B39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard-2022-223469","article-title":"Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis","volume":"82","author":"Wilkinson","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024090907513572300_keae082-B40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024090907513572300_keae082-B41","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1021\/acschembio.0c00343","article-title":"High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle","volume":"15","author":"Kinder","year":"2020","journal-title":"ACS Chem Biol"},{"key":"2024090907513572300_keae082-B42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2337\/db15-0659","article-title":"Skeletal muscle phospholipid metabolism regulates insulin sensitivity and contractile function","volume":"65","author":"Funai","year":"2016","journal-title":"Diabetes"},{"key":"2024090907513572300_keae082-B43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13075-018-1579-y","article-title":"Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis","volume":"20","author":"Raouf","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024090907513572300_keae082-B44","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s10238-023-01073-6","article-title":"Metabolic profiling of patients with different idiopathic inflammatory myopathy subtypes reveals potential biomarkers in plasma","volume":"23","author":"Zhao","year":"2023","journal-title":"Clin Exp Med"},{"key":"2024090907513572300_keae082-B45","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/rheumatology\/keab520","article-title":"Metabolomics analysis identifies a lipidomic profile in treatment-na\u00efve juvenile dermatomyositis patients vs healthy control subjects","volume":"61","author":"Dvergsten","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024090907513572300_keae082-B46","doi-asserted-by":"crossref","first-page":"e65362","DOI":"10.1371\/journal.pone.0065362","article-title":"Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15","volume":"8","author":"Franzi","year":"2013","journal-title":"PLoS One"},{"key":"2024090907513572300_keae082-B47","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"2024090907513572300_keae082-B48","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of Type I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae082\/56744600\/keae082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/SI2\/SI240\/59038579\/keae082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/SI2\/SI240\/59038579\/keae082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:53:12Z","timestamp":1725853992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/SI2\/SI240\/7601329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":48,"journal-issue":{"issue":"SI2","published-online":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae082","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,2,5]]}}}